Your browser doesn't support javascript.
loading
Efficacy of rechallenge with BRAF inhibition therapy in patients with advanced BRAFV600 mutant melanoma.
Viñal, D; Martinez, D; Espinosa, E.
Afiliação
  • Viñal D; Department of Medical Oncology, La Paz University Hospital, Paseo de la castellana 261, 28046, Madrid, Spain. dvinallozano@gmail.com.
  • Martinez D; Department of Medical Oncology, La Paz University Hospital, Paseo de la castellana 261, 28046, Madrid, Spain.
  • Espinosa E; Department of Medical Oncology, La Paz University Hospital, Paseo de la castellana 261, 28046, Madrid, Spain.
Clin Transl Oncol ; 21(8): 1061-1066, 2019 Aug.
Article em En | MEDLINE | ID: mdl-30607792
BACKGROUND: The treatment of patients with BRAFv600 mutant melanomas progressing to BRAF inhibitors (BRAFi) and immunotherapy remains challenging. Preclinical studies and a small phase 2 trials have recently suggested that rechallenging with BRAFi may have a roll in these patients. The aim of this systematic review was to summarise the current evidence on the efficacy of BRAF inhibition therapy rechallenge after progression to BRAFi in metastatic BRAFv600 melanoma patients. MATERIALS AND METHODS: We performed a systematic literature search in MEDLINE, Embase and the Cochrane Library CENTRAL up to November 2018. The target was restricted to patients with unresectable and/or metastatic BRAF V600 mutant melanoma that had previously progressed on BRAFi, were off-treatment for a period of time and then retreated with a BRAF inhibition strategy. We included prospective trials, observational studies and case reports. The primary outcomes were overall response rate (ORR), disease control rate (DCR), median progression-free survival (PFS) and median overall survival since the start of the treatment. RESULTS: Up to November 2018, nine reports met our inclusion criteria: five case reports, three observational studies and a phase 2 trial. No comparative studies have been reported. In total, 188 patients met the inclusion criteria for this review. Efficacy results of the observational reports and the clinical trial are presented. ORR varied between 28 and 43% and DCR between 57 and 72%. Duration of response was reported in 1 retrospective study and was of 14 months. PFS varied between 4.9 and 5 months and OS was not reported in all studies. CONCLUSION: Although no comparative studies have been conducted, rechallenging with BRAF inhibition therapy seems a plausible treatment option. Randomized trials are needed to confirm these results.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas B-raf / Inibidores de Proteínas Quinases / Terapia de Alvo Molecular / Melanoma / Mutação Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Espanha País de publicação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas B-raf / Inibidores de Proteínas Quinases / Terapia de Alvo Molecular / Melanoma / Mutação Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Espanha País de publicação: Itália